Brokerage Goldman Sachs has initiated buy ratings on Syngene International Ltd and Neuland Laboratories Ltd and increased target price to Rs 875 (up 20 percent) and Rs 9100 (up 46 percent), respectively, from current market price. The brokerage house also initiated sell rating on Laurus Labs Ltd with a target price of Rs 350 a share, down 23 percent.
Neuland Laboratories Ltd extended its gains and rose almost 6 percent after the company told the exchanges that the US Food and Drug Administration (FDA) completed an inspection in Hyderabad without any observations.
Neuland Lab Consolidated June 2023 Net Sales at Rs 362.99 crore, up 64.12% Y-o-Y
Neuland Labs Share Jumps 44% in 3 Days on Strong Q4 Results
The Board of Directors of Neuland Laboratories Limited has approved the appointment of Abhijit Majumdar, as the Chief Financial Officer (CFO) of the company.
SE Intimation – Appointment of CFO & Approval for transfer of Company`s property situated at Nanakramguda, Hyderabad by way of perpetual lease
The past few years have seen major changes to the ways in which drug companies and their regulators go about ensuring the safety and efficacy of drugs. The response to COVID-19 accelerated trends that were already defining an era of significant change.
Digital transformation went from a popular corporate buzz phrase to an essential survival tool with the outbreak of the COVID-19 pandemic. Industries ranging from banking and restaurants to travel and manufacturing had to re-invent their business models literally overnight.
Neuland Annual Report FY 2021-22
SE Intimation – Resignation of Chief Financial Officer